Boardroom Alpha
Boardroom Alpha
BAX · Current Report (Form 8-K) · Filed December 22, 2025

Baxter International Inc — Current Report (Form 8-K)

Form
8-K
Filed
December 22, 2025
Period
Dec 22, 2025
Ticker
BAX
Accession
0000010456-25-000025
Boardroom Alpha · Filing insights

Baxter completes final settlement of cash tender offers for 2026 and 2027 notes, up to $600 million.

About Baxter International Inc
Market cap
$9.6B
1Y TSR
−40.1%
3Y TSR
−23.8%
Board grade
C-
Sector
Healthcare
CEO
Andrew P Hider
Last annual meeting: May 5, 2026 · View full Baxter International Inc profile →
bax-20251222

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 22, 2025
Baxter International Inc. 
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
1-444836-0781620
(Commission
File Number)
(I.R.S. Employer
Identification No.)
One Baxter Parkway,Deerfield,Illinois60015
(Address of principal executive offices)(Zip Code)
(224) 948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange
1.3% Global Notes due 2029BAX 29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:



Item 8.01 Other Events.
Final Results of Tender Offers
On December 22, 2025 (the “Final Settlement Date”), Baxter International Inc. (the “Company”) effected the final settlement of the Company’s previously announced cash tender offers (each, a “Tender Offer” and together, the “Tender Offers”) to purchase (i) any and all of its 2.600% senior unsecured notes due 2026 (the “2026 Notes”) and (ii) a portion of its 1.915% senior unsecured notes due 2027 in an aggregate purchase price up to $600 million (the “2027 Notes”, and together with the 2026 Notes, the “Notes”). The Tender Offers expired at 5:00 p.m., New York City time, on December 18, 2025 (the “Expiration Time”).
As previously reported, on December 8, 2025 (the “Early Settlement Date”), the Company purchased $420,589,000 aggregate principal amount of 2026 Notes and $614,370,000 aggregate principal amount of 2027 Notes that were tendered at or prior to 5:00 p.m., New York City time, on December 3, 2025 (the “Early Tender Date”) and satisfied and discharged all outstanding 2026 Notes after giving effect to the repurchase of any 2026 Notes validly tendered in the Tender Offer and not validly withdrawn at or prior to the Early Tender Date. The Tender Offer for the 2027 Notes was fully subscribed as of the Early Tender Date and no additional 2027 Notes were accepted after that date.
An additional $2,610,000 in aggregate principal amount of the 2026 Notes were validly tendered and not validly withdrawn after the Early Tender Date and at or prior to the Expiration Time (the “Late Tender Notes”). The Late Tender Notes were accepted for purchase at a price of $960.50 per $1,000 of principal amount of such Notes (which did not include the “early tender payment” of $30), plus accrued and unpaid interest on such Notes from the last date on which an interest payment has been paid to, but excluding, the Final Settlement Date.
This Current Report on Form 8-K is neither an offer to sell nor a solicitation of offers to buy any 2026 Notes or 2027 Notes.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Baxter International Inc.
By:/s/ Joel T. Grade
Name:
Joel T. Grade
Date: December 22, 2025
Title:
Executive Vice President and Chief Financial Officer

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Baxter International Inc (BAX)

Reference

Frequently asked questions

When did Baxter International Inc file this 8-K?
Baxter International Inc (BAX) filed this Current Report (Form 8-K) with the SEC on December 22, 2025. The accession number assigned by EDGAR is 0000010456-25-000025.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Baxter completes final settlement of cash tender offers for 2026 and 2027 notes, up to $600 million. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Baxter International Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Baxter International Inc has filed under CIK 10456, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer